# Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

> **NCT05714345** · PHASE2 · TERMINATED · sponsor: **Allogene Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Relapsed/Refractory Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** ALLO-647
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **GENETIC:** ALLO-501A

## Key facts

- **NCT ID:** NCT05714345
- **Lead sponsor:** Allogene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-01
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-10-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated early for business reasons.
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714345, "Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05714345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*